PressAugust 20, 2024 Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Health & ScienceAugust 19, 2024 MindBio Reports Promising Phase 2A Results for Depression Treatment with LSD
PressAugust 16, 2024 Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
PressAugust 15, 2024 Filament Health Announces Second Quarter 2024 Financial Results and Operational Highlights
PressAugust 15, 2024 Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
Health & ScienceAugust 14, 2024 UC Davis Scientists Introduce Tool to Reveal Psychedelics’ Effects on Neurons
Health & ScienceAugust 14, 2024 Want To Work in Psychedelics? The Industry Needs More Trial Screeners.
PressAugust 13, 2024 Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
PressAugust 13, 2024 atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
PressAugust 13, 2024 Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
PressAugust 13, 2024 atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
Health & ScienceAugust 12, 2024 Denial of Lykos’ MDMA-Assisted PTSD Therapy Followed by Retraction of Related Studies
PressAugust 12, 2024 PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
PressAugust 9, 2024 Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
PressAugust 9, 2024 Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
